Selective ghrelin/GHS receptor agonist.
Ipamorelin is a pentapeptide selective ghrelin/growth-hormone secretagogue used in research of pulsatile GH release.
Selective agonism of GHS-R1a triggers GH release without significant cortisol or prolactin elevation in in-vitro models.
Peptide engages target receptor with high affinity.
Downstream intracellular pathways activate.
Gene expression and protein synthesis shift.
Measurable change in the studied biomarker.
Original pharmacology paper establishing receptor selectivity across endocrine axes.
Dose-dependent GH release with no ACTH, cortisol, FSH or LH stimulation vs. GHRP-6.
Long-term ipamorelin administration measured against vehicle on bone density.
Significant increase in cortical bone mineral content vs. controls.
Proof-of-concept RCT of ipamorelin as a ghrelin mimetic for GI motility recovery.
Shortened time to first bowel movement and tolerated solid food earlier than placebo.
Lyophilized -20°C. Reconstituted: 2–8°C, 30 days.
Strictly for in-vitro laboratory and research investigations.
Not approved for diagnostic, therapeutic, or veterinary application.
Handling restricted to licensed researchers and laboratory staff.
Warning — Ipamorelin is supplied solely for legitimate laboratory research. Any administration to humans or animals is strictly prohibited and may violate federal, state, or local law. By purchasing, the researcher accepts full responsibility for safe handling, storage, and lawful use.
